...
机译:初级耐火滤泡淋巴瘤患者组织学转型的风险
Hosp Univ Cent Asturias Dept Hematol Oviedo Spain;
Univ Modena &
Reggio Emilia Dept CHIMOMO Modena Italy;
Univ Claude Bernard Lyon 1 Hosp Civils Lyon Dept Hematol CHU Lyon Sud Pierre Benite France;
Vrije Univ Amsterdam Med Ctr Dept Hematol Amsterdam Netherlands;
Haematol Unit IRCCS Osped Oncol Ist Tumori Giovanni Paolo 2 Bari Italy;
Hosp Clin Barcelona Dept Haematol Barcelona Spain;
Univ Hosp Salamanca Dept Hematol Salamanca Spain;
Vrije Univ Amsterdam Med Ctr Dept Hematol Amsterdam Netherlands;
Univ Pisa Sect Hematol Dept Clin &
Expt Med Pisa Italy;
Inst Portugues Oncol Francisco Gentil Dept Hematol Lisbon Portugal;
Oslo Univ Hosp Oslo Norway;
Osped San Giovanni Bellinzona Oncol Inst Southern Switzerland IOSI Bellinzona Switzerland;
Queen Mary Univ London Barts Canc Inst Ctr Haematooncol London England;
Karolinska Univ Hosp Dept Hematol Stockholm Sweden;
Univ Zagreb Dept Internal Med Univ Hosp Ctr Zagreb Div Hematol Zagreb Croatia;
Italian Lymphoma Fdn FIL Modena Italy;
HUS IBSAL Dept Hematol Salamanca Spain;
Univ Claude Bernard Lyon 1 Hosp Civils Lyon Dept Hematol CHU Lyon Sud Pierre Benite France;
Univ Modena &
Reggio Emilia Modena Italy;
机译:初级耐火滤泡淋巴瘤患者组织学转型的风险
机译:组织学转型和治疗相关的髓细胞平面症/急性髓细胞白血病患者滤泡淋巴瘤患者的患者
机译:PRIMA试验一线免疫放疗后组织学改变的滤泡性淋巴瘤患者的危险因素和结果
机译:使用梯度增强树组合预测原发性干燥综合征患者的淋巴瘤结局和危险因素
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:十二指肠原发性滤泡性淋巴瘤组织学转化的一例报道
机译:组织学转型和治疗相关的髓细胞平面症/急性髓细胞白血病患者滤泡淋巴瘤患者的患者